Tabituximab barzuxetan (exclude Y90)
Tabituximab barzuxetan (exclude Y90) is a radioimmunoconjugate composed of a humanized monoclonal antibody targeting FZD-10 (OTSA-101) . Tabituximab barzuxetan shows antineoplastic activity. Tabituximab barzuxetan can be used for synovial sarcoma research[1].
Product Specifications
CAS Number
1612758-88-9
Product Name Alternative
OTSA101-DTPA; OTSA101-DTPA-90Y; OTSA101-SS01
UNSPSC
12352203
Target
Wnt
Type
ADC Related
Related Pathways
Stem Cell/Wnt
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/tabituximab-barzuxetan.html
Solubility
10 mM in DMSO
Smiles
[Tabituximabbarzuxetan(excludeY90)]
References & Citations
[1]Anne-Laure Giraudet , et al. A first-in-human study investigating biodistribution, safety and recommended dose of a new radiolabeled MAb targeting FZD10 in metastatic synovial sarcoma patients. BMC Cancer. 2018 Jun 8;18 (1) :646.
Shipping Conditions
Room temperature
Scientific Category
ADC Related
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
TRC-N500000-25MG 25 mg
p-Nitrophenyl 2-Acetamido-2-deoxy-a-D-galactopyranoside
Sign In for Pricing
View Details